idecabtagene vicleucel + BMS-986405

This combination therapy consists of **idecabtagene vicleucel**, an autologous CAR-T cell therapy targeting B-cell maturation antigen (BCMA) on malignant plasma cells, combined with **BMS-986405**. Idecabtagene vicleucel is engineered from a patient’s own T cells, modified ex vivo to express a chimeric antigen receptor (CAR) that recognizes BCMA, leading to targeted immunologic destruction of myeloma cells. This therapy is approved for the treatment of adults with relapsed or refractory multiple myeloma after multiple prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. BMS-986405 is a proprietary anti-BCMA monoclonal antibody developed to be co-administered with idecabtagene vicleucel, potentially for enhancing efficacy or managing resistance. The combination is currently being investigated in clinical studies for multiple myeloma[1][2][3][4].

Other names

anti-BCMA CAR T cellautologous CAR-T therapy targeting BCMAide-cel + BMS-986405